Heron Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Heron Therapeutics Stock Forecast and Price Target
Heron Therapeutics's stock is projected to advance by 149.04% from the previous closing price if it reaches the average target of $6.50 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $9.00 and a low-end estimate of $5.00. Even if not interested in HRTX stock, you may want to be aware of its competitors.
149.04% Upside
Heron Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Heron Therapeutics's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $2.80 – an increase of 100.00%. The Heron Therapeutics forecast is for Fair Value to reach $5.29 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.27 | Buy/Sell | $174.55 | 13.89% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$127.51 | Buy/Sell | $130.51 | 12.15% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF217.30 | Buy/Sell | CHF307.83 | 25.40% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.30€ | Buy/Sell | 102.80€ | 19.39% |
| 4151 Stock Forecast | Kyowa Kirin | Outperform |
18
|
¥2.67k | Buy/Sell | ¥3.06k | 12.46% |
Heron Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Heron Therapeutics's Revenue has increased by 21.47%, going from $88.64M to $107.67M. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $156.56M – an increase of 45.41%. The Heron Therapeutics forecast is for Revenue to reach $461.80M or grow by 328.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.03 | Buy/Sell | $8.50 | -100.00% |
| ACRX Stock Forecast | AcelRx Pharmaceuticals | Buy |
6
|
$1.02 | Buy/Sell | $4.63 | 402.94% |
| TRVN Stock Forecast | Trevena | Outperform |
2
|
$0.61 | Buy/Sell | $5.18 | 555.74% |
.jpg)
Heron Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Heron Therapeutics has seen a decline in its EBITDA, from $-219.72M to $-166.37M – a 24.28% decrease. The next year looks promising for Heron Therapeutics, with analysts predicting EBITDA of $-199.94M – an increase of 20.18%. Over the next eight years, experts anticipate that Heron Therapeutics's EBITDA will grow at a rate of 22.54%.
Heron Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Heron Therapeutics's EBIT has decreased by 23.95%, from $-222.56M to $-169.26M. For the next year, 3 analysts project Heron Therapeutics's EBIT to drop by 45.23%, reaching $-92.71M. By 2030, professionals believe that Heron Therapeutics's EBIT will decrease by 198.55%, reaching $166.80M – a concerning trend for the company.
Heron Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Heron Therapeutics's EPS has increased by 100.00%, going from $-2.50 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $-0.43 – an increase of 100.00%. The Heron Therapeutics forecast is for EPS to reach $1.25 or grow by 100.00%.
.jpg)